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Deep vein thrombosis (DVT) is a potentially deadly medical condition that is costly to treat and
impacts thousands of Americans every year. DVT is characterized by the formation of blood clots
within the deep venous system of the body. If a DVT dislodges it can lead to venous thromboembolism
(VTE) and pulmonary embolism (PE), both of which can lead to significant morbidity or death.
Current treatment options for DVT are limited in both effectiveness and safety, in part because the
treatment of the DVT cannot be confined to a defined sequestered treatment zone. We therefore
developed and tested a novel thrombectomy device that enables the sequesteration of a DVT to a
defined treatment zone during fragmentation and evacuation. We observed that, compared to a
predicate thrombectomy device, the sequestered approach reduced distal DVT embolization during
ex vivo thrombectomy. The sequestered approach also facilitated isovolumetric infusion and suction
that enabled clearance of the sequestered treatment zone without significantly impacting vein wall
diameter. Results suggest that our novel device using sequestered therapy holds promise for the
treatment of high risk large-volume DVTs.
Venous thromboembolism (VTE) is the third most common vascular disease in the world1, and leads to an
estimated 60,000-100,000 annual deaths in the US a nnually2. Deep vein thrombosis (DVT) is one of the major
causes of VTE, and occurs when abnormal blood clots (thrombus) develop within the venous s ystem2. Venous
thrombus can disassociate and travel into the pulmonary arteries, causing a potentially fatal pulmonary embolism (PE)3. Individuals with large-volume DVTs in the proximal veins of the pelvis and abdomen (in the iliac
veins and vena cava) are at higher risk of suffering a PE4. Therefore, there is a pressing need for effective and safe
treatment options for the management of higher risk large-volume DVTs.
Two widely used options exist for the treatment of patients with large-volume DVTs in the large veins of
the abdomen and pelvis (Fig. 1), but both have significant limitations. Both of these approaches involve endovascular insertion of catheter devices to perform thrombectomy (fragmentation and/or removal of DVT). The
first of these treatment options utilizes percutaneous mechanical thrombolysis catheters. These aim to fragment
and dissolve large-volume DVT within the venous lumen into smaller fragments (Fig. 1, left panel). However,
this fragmentation comes with the risk of damaging the inner vein wall during the mechanical sheering of
thrombus5,6. Additionally, the procedure is associated with high risk of distal embolization, in which smaller
thrombus fragments travel with the venous blood flow to the heart and lungs causing a PE.
An alternative treatment option is suction thrombectomy (Fig. 1, middle panel). Here, suction devices
inserted through the vasculature are used to debulk large-volume DVT via negative pressure evacuation. However, suction comes with a risk of vein wall collapse, which can lead to trauma on the inner lumen of the vessel,
as well as risk of distal embolization of thrombus fragments that separate from the main thrombus but are not
successfully removed7. Additionally, substantial blood loss can occur during these procedures as thrombus fragments are removed along with variable quantities of blood volume.
Given the inherent limitations of existing mechanical and suction thrombectomy devices, we proposed a
multi-modal design that sequesters the treatment zone (Fig. 1, right panel). The aim of this novel device would
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Figure 1.  Comparison of traditional thrombectomy treatment options and a novel multi-modal sequestering
thrombectomy catheter. The graphics in this figure were drawn by Matt Holt (medical-illustrator@bodyrender.
com).

be to reduce the risk of distal thrombus embolization during a thrombectomy procedure. Additionally, the device
would allow sequestered flushing of thrombus fragments within the defined treatment zone without traumatically
impacting the vein wall. We hypothesized that in an ex vivo setting, this novel sequestering thrombectomy device
would effectively remove thrombus, reduce distal embolization, and prevent vein wall over-distension or collapse.

Methods

Prototype of a catheter with a sequestered treatment zone. A thrombectomy device that seques-

tered a treatment zone between two balloons was developed in collaboration with Nordson Medical, Inc. (Marlborough, MA). The multi-modal sequestered thrombectomy catheter (MMSTC), was made of multiple extruded
tubes, with multiple inner lumens. The proximal, outermost catheter was 1 meter long, and had an outer diameter of 7.33 mm (22 French (Fr), where 1 Fr = 1/3 mm is the standard unit to measure diameters of catheters)
and an inner diameter of 7 mm (21 Fr). The proximal catheter was made of polyether block amide (Pebax 5533,
Arkema, Colombes, France), and coated to make the surfaces hydrophobic. This catheter was inserted over a
guide wire (0.889 mm (0.035 inch) diameter stainless steel wire), and terminated in a proximal balloon that
could be inflated to demarcate and seal the the proximal end of the treatment zone (left side, Fig. 2A).
The second component of this device was a thinner but longer distal catheter that could be inserted over the
same guide wire through through the lumen of the proximal catheter (right side, Fig. 2A). This terminated in a
second, distal balloon that defied the distal end of the treatment zone. Inside distal catheter was 1.1 m long and
had a 2.33 mm (7 Fr) outer diameter. This multi-lumen extrusion was made of nylon 12 ([(CH2)1 1C(O)NH]n ).
The distal catheter included flush ports that enable the surgeon to infuse drugs such as thrombolytics, and also to
subsequently introduce fluid to the treatment zone that flushes fragments of thrombus down one of the lumens
of the proximal catheter; simultaneous suction can be applied to that lumen.
The MMSTC included a center-line, rail-mounted mechanical agitator for the purpose of fragmenting thrombus, and aimed to do so while minimizing the risk of vein wall contact and trauma. The plastic agitator measured
5 mm × 15 mm and tracked over the outer surface of the distal catheter and that could be moved independently
within the treatment zone to fragment thrombus and using 1mm stainless steel wire cannulas.
The user end of the device utilized standard luer-lock components from the Nordson Medical, Inc. catalog
which were over-molded onto the thrombectomy device. The MMSTC thus integrated both mechanical and suction thrombectomy modalities to remove large-volume DVTs within a sequestered region of vascular segment.
The catheter’s adjustable double-balloon system aimed to isolate and sequester the treatment zone to avoid distal
thrombus embolization during treatment sessions. As described below, we tested the hypothesis that, in an ex vivo
system with an artificially generated blood clot, the MMSTC catheter system would effectively remove thrombus
fragments, reduce distal embolization, and prevent vein wall over-distension or collapse.
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Figure 2.  (A) Components of the multi-modal sequestering thrombectomy catheter that isolates the treatment
zone. (B) Comparison of infusion only, suction only, and infusion and suction modes of catheter operation to
evacuate thrombus fragments within the isolated treatment zone.

Isovolumetric flushing of the sequestered treatment zone. The MMSTC catheter system facilitated
isovolumetric infusion and suction through simultaneous infusion and suction of liquid in the sequestered treatment zone (Fig. 2B) with the aim of minimizing vein wall distension or collapse during evacuation of thrombus
fragments. This was achieved via a linear actuator device to simultaneously infuse and suction fluid through the
treatment at equal volumetric flow rates (Fig. 3).
The linear actuator was composed of a motor-powered cart which followed a lead screw along the axis of the
device and displaced a 3D printed coupler that connected to the the plungers of two 500 ml syringes. Movement
of the coupler thus depressed the plunger of one syringe while retracting the plunger of the other syringe at the
same rate. Surgical tubing connected the end of the positive pressure syringe to the to the infusion lumen of the
distal catheter, and connected the end of the negative pressure syringe to the evacuation lumen of the proximal
catheter. A pressure gauge was mounted between the positive pressure syringe and the infusion lumen.
A US National Electrical Manufacturers Association (NEMA) standard size 23 motor (faceplate 58 × 58 mm)
was used to drive the cart, and was controlled by a microcontroller (Arduino Mega 2560 Rev3, Arduino, Ivrea,
Italy), a Tb6560 motor driver (TB6560 3-axis stepper motor controller, Hailege, Shenzen, China), and a 24 V DC
power supply (RS-150-24, Mean Well, Taipei, Taiwan). A range of motor speeds was tested.
Thrombectomy testing in an ex vivo setting. The efficacy of the MMSTC and an industry-standard
catheter (Indigo CAT 5 Fr, Penumbra, Alameda, CA) were assessed in an ex vivo circulation system that contained a model thrombus within a segment of 19.05 mm diameter clear vinyl tubing (3/4” ID clear vinyl tubing,
Abbott Rubber Company, Inc, Itastca, Illinois, USA). Both devices use a combination of suction and physical
disruption of the thrombus to treat thrombus. Each was used to treat a section of in-lab made thrombus for 30
s, an interval of time that is clinically relevant for our own surgical practice, and device efficacy was assessed by
the weight of thrombus collected after 30 s of treatment.
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Figure 3.  A top-down view of the linear actuator used in conjunction with the Hydra Catheter.

Figure 4.  (A) The laboratory flow model consisted of (counter-clockwise, beginning in the lower left) a
saline reservoir (1); a pump (2); a valve that enabled introduction of a catheter and allowed for overflow (3); a
visualization chamber that supported either a clear tube or a segment of porcine vena cava with a laboratorymade thrombus (4); and a filtered return that enabled collection of any embolized thrombus (5). The MMSTC
device is shown entering the setup at the insertion point. (B) The Penumbra device is shown entering the
insertion point. C) A zoomed in view of the treatment area/thrombus model of the laboratory flow model.

Model thrombus generation. Our model thrombus model for these experiments was created by mixing bovine
blood, deionized water, and flour for a thickening agent. Sourcing bovine blood from a local meat packing plant
(Star Packing Company, St. Louis, Missouri, USA), a 6.5 mL mixture of 6:4 blood to water was mixed together
with one teaspoon of flour as a thickening agent. Next, this mixture was poured into a portion of flexible vinyl
tubing and allowed to rest in a 4 degree Celsius refrigerator for 24 h. The next day blood that had risen to the
surface of the mixture was drained and another teaspoon of flour was mixed into the solution. The final mixture
was allowed to rest at 4 degrees Celsius for another 24 h.
Laboratory flow model. The testing setup used to assess catheter performance and the mass of distal emboli
generated during a simulated surgical thrombectomy consisted of a reservoir of water that was pumped through
a segment of model thrombus within a tube at a rate of 1500 ml/s using a chemical pump (3388 Variable-Flow
Chemical Pump, Control Company, Webster, Texas, USA). The setup (Fig. 4) consisted of a main central channel housing the thrombus and treatment zone, with the model thrombus supported in by a 3D printed holder. A
port allowing introduction of a catheter was included, as was an alternate overflow route representing peripheral
vasculature that accommodates blood return in the case of venous blockage. This also helped prevent the introduction of air into the system. The treatment zone drained to an outlet hose that sent passed saline and distal
emboli to a mesh sieve with a coffee filter (porosity of 10 − 20 µm, Simply B
 estTM 8-12 cup coffee filters, Topco
Associates,LLC, Elk Grove Village, Illinois, USA) paper, for collection of distal emboli. In all experiments, the
chemical pump was run and allowed to fill the flow setup tubing until no air bubbles were evident visually.
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Simulated surgical thrombectomy procedures. To test the MMSTC, the catheter was introduced through the
catheter port (right side, Fig. 4), the proximal balloon was inserted and then inflated, and the distal catheter was
then advanced through the model thrombus and its balloon inflated. An endoflator (BasixTouchTM Inflation
Device, Merit Medical, South Jordan, Utah, USA) was used to inject a 1:1 mix of contrast agent and deionized
when filling balloons. The linear actuator was used at a motor speed of 300 RPM to infuse liquid and suction
thrombus while the agitator was displaced along the length of the treatment zone to disrupt the thrombus segment. After 30 s, the thrombus collected in the linear actuator was collected in a pre-weighed coffee filter and
allowed to dry overnight (cf.8) to calculate the dry weight of the total thrombus collected.
To test the predicate Penumbra Indigo 5 Fr catheter, an Indigo CAT 5 Fr Separator (Penumbra, Alameda, CA)
was used to fragment the thrombus, and a vacuum regulator, tubing, and 1000 mL collection canister set (Gomco
Model 405 Table Aspirator, Allied Healthcare Products Inc, St. Louis, Missouri, USA) was used to generate suction and collect thrombus. The vacuum pump was set to 75 kPa (22.5 inHg) of pressure. The thrombus collected
in the collection canister was collected on filter paper, dried overnight, and weighed.

Quantification of distal embolization in situ. Both devices were tested to assess the amount of distal
embolization generated during a simulated thrombectomy conducted in the flow circuit described above. A
piece of tubing filled with the simulated thrombus described above was attached to the 3D printed housing in
the flow circuit. A catheter was inserted into the flow setup as described above.
For the MMSTC, to test the efficacy of the sequestered approach to thrombectomy, the balloons were either
left uninflated (control), inflated 50%, or inflated 100% as above. For the MMSTC, the agitator was used to fragment the thrombus, and the isovolumetric pump was engaged. While this treatment proceeded over 30 s, any
thrombus that escaped the sequestered treatment zone was collected in the pre-weighed coffee filter and its dry
weight recorded.
For the Penumbra Indigo 5 Fr device, the same setup was used, but as above, instead of the linear actuator,
the Gomco Allied 406 Vacuum regulator was used at 85 kPa (25 mmHg) to induce suction in the catheter, and
a Penumbra separator (Indigo System CAT 5 Separator, Penumbra Inc., Alameda, CA) was used in place of the
Hydra agitator to break up the thrombus.
Measurement and prediction of vein wall distention and collapse ex vivo. To assess how the
MMSTC system strained the vessel wall during isovolumetric evacuation of the sequestered treatment zone, the
degree to which the process distorted the vein wall was monitored by tracking the hoop stretch ratio θ (p) in a
bovine vena cava specimen acquired from a local abattoir that was inserted in place of the model thrombus and
clear tubing in the flow loop. The stretch ratio followed:
θ (ω) = d(ω)/D

(1)

where D is the initial diameter of the vena cava, and d(ω) is the steady state diameter for running of the syringe
driver motor at a rotational speed ω . Vena cava segments were stored at 4 ◦ C in 10% formalin, then tied to two
connectors at the center of the flow loop using hose clamps. For these tests, the MMSTC was inserted into the
vena cava segment and the balloons were inflated to 100%. Before the experiment, the original diameter, D, of
the middle cross-section of the vena cava was measured using a set of calipers. After this, the linear actuator was
operated in one of three ways. First, the rotational speed-stretch ratio relationship was measured only the infusion syringe connected to the MMSTC, but not the suction syringe (infusion only). Second, The relationship was
measured with the suction syringe but not the infusion syringe connected to the MMSTC (suction only). Finally,
the relationship was measured with both syringes connected (isovolumetric mode). While the linear actuator
was running the diameter, d(ω), of the middle cross-section of the vena cava was taken again with the calipers.
This process was repeated three times for each mode at 200, 300, and 400 motor RPM.
For comparison, two mathematical models for the mechanical behavior of a thin walled tube were studied.
The first was a model of a hyperelastic tube under inflation, which, as described in the supplement, which predicts
how inflation pressure, p, relates to θ:

p = 4µ

H
(2θ − 1)
1/3
R (28θ − 10
θ )

(2)

where H is the thickness of the vein prior to inflation, R is the radius of the vein prior to inflation, and C1 is the
shear modulus of the vein.
The second was the classical Bryan solution for the buckling pressure pcritical of a long tube that is clamped
at its e nds9:
 3
1
pcritical
H
=−
(3)
µ
2(1 − ν) R
where ν = 0.5 is Poisson’s ratio for the vein wall.

Statistics. Differences between means was assessed using one-way ANOVA, with a 5% false positive rate
taken as the threshold for statistical significance. All results were reported as mean ± standard error to the mean.
Each experiment was repeated a minimum of three times.
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Figure 5.  (A) Thrombus evacuated by the MMSTC in a typical experiment, viewed on filter paper, over the
course of a 30 s treatment within the flow system. (B) Thrombus evacuated by the Penumbra Indigo CAT 5
Fr catheter in a typical experiment, viewed on filter paper, over the course of a 30 s treatment within the flow
system. (C) The MMSTC evacuated significantly more thrombus than the Penumbra Indigo CAT 5 Fr catheter
under these conditions ( p = 0.005).

Results

Thrombectomy efficiency. Both the MMSTC and the Penumbra Indigo CAT 5Fr catheter removed substantial thrombus when used for 30 s in our flow system to remove a model thrombus. The MMSTC removed
significantly more thrombus over this time interval: the Penumbra Indigo CAT 5 Fr catheter removed 27± 3.14
mg, while the MMSTC removed 87± 3.86 mg ( p = 0.005 using one-way ANOVA; Fig. 5). The flow model was a
crude representation of a vascular surgical treatment zone since it does not have the variable shape and mechanics of a natural in vivo venous structure. The metric chosen for device performance in this ex vivo model was
therefore not the fraction of thrombus removed, but rather the size distribution of thrombus particles collected
in the distal filter spliced into the flow model. The latter was considered critical since successful multi-modal
suction of the thrombus particles is highly dependent on thrombus fragmentation to avoid obstruction of the
suction catheter by large thrombus pieces.
Sequestering the treatment zone decreased distal embolization of thrombus. Distal thrombus
embolization was evaluated in both catheters. To test the hypothesis that the sequestering of the treatment zone
reduced distal embolization, the MMSTC was operated with the balloons that sequester the treatment zone
inflated to 0%, 50%, or 100% of the maximum inflation (Fig. 6A–C). We additionally compared the MMSTC to
the Penumbra Indigo CAT 5 Fr catheter that does not have a distal embolization protection feature.
The average dry weight that converted into distal emboli for the MMSTC was 1.09 ± .10 g at 0% balloon
inflation, 0.266± .02 g at 50% balloon inflation, and 0.138± .02 g at 100% balloon inflation (Fig. 6D–G). This
indicated that balloon encapsulation of a sequestered treatment zone did indeed significantly reduce distal
embolization ( p < 0.0001, one-way ANOVA). The difference between 100% balloon inflation and 50% balloon
was also significant (87.4% relative decrease, p = 0.015).
To assess this issue in a real vein, the procedure was repeated once more, this time in a bovine vena cava segment containing a model thrombus generated as with the thrombi in plastic tubes. With the MMSTC inflation
at 0%, 50%, and 100%, the average amount of thrombus embolus was 0.347± .0058 g, 0.190 ±.061 g, and 0.057
± .010 g, respectively ( p = 0.039; (Fig. 6H–K)).
When comparing the Penumbra Indigo 5 Fr catheter under identical conditions to the MMSTC ex vivo test,
2.69 ± .254 g of distal thrombus emboli. This difference of over an order of magnitude was statistically significant
compared to the sequestering MMSTC ( p = 0.002, (Fig.7A–C)).The Penumbra Indigo 5 Fr catheter was also
compared to the MMSTC under identical in situ conditions. The weight of distal emboli collect was found to be
3.16 ± .221 g of thrombus. Under the same conditions, the weight of distal emboli generated from the MMSTC
was found to be 0.01 ± .001 g of thrombus, a difference of over an order of magnitude which was statistically
significant ( p < 0.0001, (Fig.7D–F)). Note that the distal thrombus was larger in the ex vivo model than in the
in situ model because of the flexibility of the vessel wall compared to that of the clear tubing of the flow model.
Isovolumetric infusion and suction through the MMSTC. To interpret the response of a vena cava
segment to isovolumetric infusion, we first studied the response of an idealized thin, hyperelastic tube to suction
and positive pressure. The response to a positive pressure is initially compliant locks up at a critical stretch of
1.41. In compression, the tube would have an initially similar compliance. However, the Bryan buckling pressure
is exceeded at a pressure of p/µ between 0.001 and 0.03 for the range of thicknesses H/R considered. Thus, the
prediction is that the deformation in response to a suction would be a buckling collapse of the tube (Fig. 8A).
We evaluated these responses in a bovine vena cava specimen ex vivo, without a thrombus. The slope of the
relationship between pump speed and stretch ratio in the vena cava in suction (Fig. 8B) was much greater than
that positive pressure (Fig. 8C). Because pressure increases monotonically with pump speed, this was indicative
of buckling in suction as seen in (Fig. 8A).
However, when isovolumetric infusion and suction were performed simultaneously, we observed only a 0.8%
increase in vena cava diameter and wall stretch (Fig. 8D). This did not represent a statistically significant change
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Figure 6.  (A–C) Multi-modal sequestering thrombectomy catheter (MMSTC) with sequestering distal embolic
balloon inflated at 0%, 50%, and 100% in ex vivo testing apparatus. (D–F) Representative distal emboli collected
on filter paper in the laboratory flow system with MMSTC balloons inflated at 0%, 50%, and 100%. (G) The
balloons caused a significant reduction in distal embolization. (H–J) Representative distal emboli collected on
filter paper in the laboratory flow system with MMSTC balloons inflated at 0%, 50%, and 100%, in a bovine vena
cava segment. (K) The balloons again caused a significant reduction in distal embolization.All scale bars: 2 cm.
(p=0.12). When all three different treatment types where compared to one another we observed that there was
a significant difference between treatment type (two-way ANOVA; p=0.04).

Discussion

Distal embolization, vein wall damage, and intraoperative bleeding are important variables when considering procedural safety and outcomes. The multi-modal sequestered therapy may hold promise for treatment
of individuals who have suffered a large-volume DVT. The MMSTC prototype demonstrated effective thrombus removal, significant reduction of distal embolization, and a mechanism to decrease vein wall collapse and
over-distension during flushing of a defined treatment zone. Furthermore, results with the MMSTC suggest
incremental benefits over predicate devices that are already in clinical practice such as the Penumbra Indigo
CAT 5 Fr suction thrombectomy catheter. Compared to predicate device, the MMSTC demonstrated a higher
thrombectomy efficiency and reduced risk of distal embolization.
The adjustable double-balloon design of the MMSTC was effective at sequestering the thrombus and decreasing distal embolization in an ex vivo flow model. Previous studies have used similar thrombosis circuits to evaluate embolus volume, size, and particle c ounts10–14. One study identified that particle counts resulting from distal
thrombus emboli can vary in size depending on the type of thrombolyic used13. Another study also demonstrated
that distal embolization was a common observation with current mechanical thrombectomy devices, highlighting
the need for improved next-generation technology that can minimize the risks of distal embolization10.
Clinically, the risk of distal thrombus embolization has been widely reported4,5,15–17. Although it is likely
that these events are under-reported, when they do occur, they can lead to catastrophic events including severe
hemodynamic compromise, need for invasive measures such as extracorporeal membrane oxygenation (ECMO),
or even death. In a recent registry of 234 patients who underwent suction thrombectomy for large volume DVTs
in the vena cava and right heart, there were reported 36 procedure-related complications (15%). Among these
complications, one patient with vena cava DVT had intraprocedural distal emboliration leading to a massive PE
and subsequent death. Of note, transfusion occurred in 59 procedures (25.2%), and in 5% of these patients >3
unites of blood were needed18.
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Figure 7.  (A) Representative distal emboli collected from the MMSTC device ex vivo. (B) Representative
distal emboli collected from the Penumbra Indigo 5 Fr device ex vivo. (C) The MMSTC device produced more
than an order of magnitude less distal embolization than the Penumbra device under identical conditions.
(D) Representative distal emboli collected from the MMSTC device in situ. (E) Representative distal emboli
collected from the Penumbra Indigo 5 Fr device in situ. (F) The MMSTC device produced more than an order of
magnitude less distal embolization than the Penumbra device under identical conditions. All scale bars: 2 cm.
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Figure 8.  (A) A model of the response of a hyperelastic tube to suction and positive pressure loading. The
dashed lines represent states that are not achievable due to buckling in compression or material lock-up in
tension. (B) Change in vena cava diameter (proportional to stretch ratio θ ) during suction only using the
MMSTC. (C) Change in vena cava diameter during infusion only using the MMSTC. (D) Change in vena cava
diameter during isovolumetric infusion using the MMSTC.
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The vena cava wall is a highly compliant structure, which is essential for venous capacitance and blood return
to the heart depending on an individual’s volume status. With hypovolemia the vein will naturally be constricted,
and with hypervolemia the vein wall will be more compliant and distended19,20. However, rapid collapse and
over-distension of the vein wall is presumed to cause vein wall micro-trauma, which can lead to denuding of the
endothelium, elastin fiber fragmentation, and risk of vein lumen thrombosis or internal b
 leeding21.
To date, there is no constitutive relationship or derivation for the vena cava or the venous vasculature in
general. Therefore, while the model presented in our study has its limitations (as it relies on constitutive relationships originally defined for rubber biomaterials) it does provide a new method to predict venous wall failure
due to excesses suction/infusion pressures through the MMSTC. Simultaneous suction and infusion through
the MMSTC led to a 17% change in venous wall diameter (Fig. 5), which is far below the theoretical limit of
41% predicting vein wall bursting. There is a paucity of ex vivo data that evaluates this process, but our system
demonstrated that isovolumetric flow within a vena cava tissue segment can indeed prevent vein wall collapse
and over-distension (Supplementary Material).
Our study results provide a foundation for a sequestered approach to DVT treatment with multi-modal
thrombectomy. We anticipate that future pre-clinical studies will help further validate this approach as an effective and safe alterative to existing venous thrombectomy procedures. Future studies will optimize infusion and
suction parameters through the MMSTC, which will utilize proximal and distal balloons that can accommodate
a wide range of venous diameters. Additionally, testing of the multi-modal thrombectomy catheter will need to
be transitioned to an in vivo models to evaluate feasibility and preliminary efficacy of this novel device (Supplementary Material).
Received: 19 September 2021; Accepted: 4 March 2022
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